Ownership and insider activity for Aytu BioPharma, Inc. (AYTU): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets.
Price
| Price | $1.97 |
| Market Cap | $21M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-28 | Disbrow Joshua R. | A-Award | 30,000 | |
| 2026-07-28 | PYSZCZYMUKA GREG | A-Award | 20,000 | |
| 2026-07-28 | Disbrow Jarrett | A-Award | 15,000 | |
| 2026-07-28 | Selhorn Ryan J | A-Award | 25,000 | |
| 2026-07-28 | LIU VIVIAN H | A-Award | 10,000 | |
| 2026-07-28 | JAIN ABHINAV | A-Award | 10,000 | |
| 2026-07-28 | DOCKERY CARL | A-Award | 10,000 | |
| 2026-07-28 | Donofrio John Jr. | A-Award | 10,000 | |
| 2025-06-30 | DOCKERY CARL | |||
| 2025-10-03 | PYSZCZYMUKA GREG | A-Award | 12,500 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.1M | $802328 | $7.0M | $11.0M | $48.1M | $49.6M | $19.4M | $23.0M | $20.0M | $31.0M |
| Short-term Investments | $1.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $162427 | $528039 | $578782 | $1.7M | $5.6M | $28.2M | $21.7M | $28.9M | $23.5M | $31.2M |
| Inventory | $524707 | $1.3M | $1.3M | $1.4M | $10.0M | $16.3M | $10.8M | $12.0M | $12.1M | $11.4M |
| Total Current Assets | $10.1M | $3.0M | $9.5M | $15.4M | $75.4M | $105.2M | $59.9M | $72.8M | $61.9M | $79.2M |
| Property, Plant & Equipment | $231430 | $647254 | $219000 | $203733 | $893000 | $8.7M | $6.3M | $3.9M | $1.5M | $1.6M |
| Goodwill | $221000 | $238426 | 0 | 0 | $28.1M | $65.8M | 0 | 0 | 0 | 0 |
| Intangible Assets | $13.6M | $11.1M | $11.4M | $19.1M | $48.9M | $85.5M | $70.6M | $59.0M | $52.5M | $42.2M |
| Total Assets | $24.3M | $15.0M | $21.1M | $34.7M | $153.3M | $265.7M | $137.6M | $137.8M | $118.9M | $124.2M |
| Accounts Payable | $2.3M | $2.2M | $2.1M | $2.1M | $11.6M | $19.3M | $11.0M | $13.5M | $10.3M | $10.6M |
| Short-term Debt | 0 | 0 | 0 | 0 | $982000 | $24.6M | $3.8M | $8.7M | $4.3M | $10.9M |
| Total Current Liabilities | $10.1M | $3.6M | $3.4M | $5.4M | $28.8M | $109.4M | $64.4M | $69.0M | $62.2M | $63.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $2.8M | $14.2M | $20.9M | $10.9M | $10.9M |
| Total Liabilities | $14.3M | $11.0M | $7.6M | $27.6M | $58.3M | $128.1M | $93.3M | $98.5M | $91.1M | $105.2M |
| Retained Earnings | -$46.6M | -$69.1M | -$79.3M | -$106.4M | -$120.0M | -$178.3M | -$287.1M | -$304.1M | -$320.0M | -$333.5M |
| Total Equity | $10.1M | $4.0M | $13.4M | $7.1M | $95.0M | $137.6M | $44.3M | $39.4M | $27.7M | $19.0M |
| Total Debt | 0 | 0 | 0 | 0 | $2.0M | $31.0M | $18.2M | $30.4M | $16.4M | $22.9M |
| Net Debt | -$9.1M | -$802328 | -$7.0M | -$11.0M | -$46.1M | -$18.7M | -$1.2M | $7.4M | -$3.6M | -$8.0M |
| Working Capital | $15802 | -$581906 | $6.1M | $10.1M | $46.7M | -$4.2M | -$4.5M | $3.8M | -$337000 | $16.1M |
Financial Health
| Debt / Equity | 0.65 |
| Current Ratio | 1.12 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -3.20 |
Profitability
| Return on Equity | -148.91% |
| Return on Invested Capital | -23.62% |
| Return on Assets | -30.49% |
| Gross Margin | 62.50% |
| Operating Margin | -26.79% |
| Net Margin | -60.17% |
Related companies: ADAP · ALUR · ANL · BFRI · EKSO · GOVX · NVNO
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of AYTU: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks